The Uromigos
By The Uromigos
Hosted by Brian Rini and Tom Powles
Brian Rini MD is Chief of Clinical Trials, Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Centre
Tom Powles is Director of Barts Cancer Centre, St Bartholomews Hospital and Professor or Genitourinary oncology, Queen Mary University of London
The UromigosMay 21, 2021
Episode 317: AUA 2024 Preview with the AUA Secretary
Episode 316: APCCC 2024 Summary with Silke Gillessen
Episode 315: APCCC 2024 Quickfire - Bone health, hot flashes and gynecomastia in prostate cancer
Episode 314: APCCC 2024 Cardiovascular risks with hormone therapy in prostate cancer
Episode 313: APCCC 2024 Debate - Radiation therapy in advanced disease
Episode 312: APCCC 2024 Radiation therapy after surgery for prostate cancer
Episode 311: The Uromigos Paper of the Month - The POUT Trial
Alison Birtle describes adjuvant chemotherapy in bladder cancer.
Episode 310: Dosing and duration of drugs from a cost perspective
Episode 309: EAU24 Checkmate 274 - OS for adjuvant nivolumab in bladder cancer
In this second part, Matt Galsky describes the OS signal data. We also look into the future.
Episode 308: EAU24 IMVIGOR 011 - Outcome of ctDNA negative patients post-cystectomy
Tom, Brian and Matt Galsky review the screening component of this study, presented at EAU24.
Episode 307: Bladder-Sparing Approaches Part 2
Episode 306: The Uromigos Paper of the Month - Chemo/Nivo as a bladder sparing approach in UC
Episode 305: FDA and Oncology Clinical Trials
Episode 304: A PSMA CD3 Bispecific T-cell Engager in CRPC
Episode 303: Community GU Oncology
Episode 302: Part 2- Adjuvant Therapy in solid tumors
Hans Hammers discusses trial design and patient selection in the adjuvant setting.
Episode 301: Cancer research from a global perspective.
Episode 300: Adjuvant PD1 Therapy in Solid Tumours
Episode 299: Androgen receptor ligand-directed degrader BMS-986365
Episode 298: ASCO GU 2024 Highlights
Silke, Tom and Brian cover the bases.
Episode 297: ASCO GU 2024: CONTACT2 Part 2 - The Aftermath
Episode 296: ASCO GU 2024: Novel approaches to QOL and belzutifan
Episode 295: ASCO GU 2024: Adjuvant Therapy in Renal Cancer
Episode 294: ASCO GU 2024: Adjuvant Pembrolizumab in Bladder Cancer
Episode 293: ASCO GU 2024: BRCAaway and CONTACT2
Episode 292: ASCO GU 2024: HPN328 - A Tri-Specific T Cell Engager in Prostate Cancer
Episode 291: ASCO GU 2024: CONTACT2 - Cabozantinib and Atezolizumab in Prostate Cancer
Episode 290: ASCO GU 2024 Preview
Episode 289: The Uromigos Paper of the Month - TALAPRO2 in Nature Medicine
Episode 288: APCCC #3: Controversies around Radiotherapy
Episode 287 APCCC: Early Discontinuation of Therapy in HSPC
Episode 286: APCCC Prostate Cancer Meeting Overview
Episode 285: Holiday Special: Renal Cancer in 2023
Episode 284: Tres amigas: Lo más destacado del cáncer en urología en 2023
Elena Castro, Begoña Valerrama y Cristina Suárez analizan lo más destacado del cáncer en urología en 2023
Episode 283: Holiday Special: Prostate Cancer in 2023
Tanya Dorff discusses her favourite prostate cancer studies of the year.
Episode 282: Holiday Special: Bladder Cancer in 2023
Episode 281: The Uromigos Paper of the Month - Lu-177 with Pembrolizumab in Prostate Cancer
Rahul Aggarwal describes his phase 1/2 study with only 1 cycle of Lu-177 in CRPC.
Episode 280: IKCS 2023 Overview
An apology
Episode 279: Management of IO-resistant RCC at #UromigosLive 2023
Episode 278: Current and Future Status of Radioligand Therapy at #UromigosLive 2023
Episode 277: NMIBC Discussion at #UromigosLive 2023
Tom is joined by Sam Chang, Sia Daneshmand, and Petros Grivas to discuss new therapies in non-muscle invasive bladder cancer, including those for BCG-refractory NMIBC and the cretostimogene + pembrolizumab combo for BCG-unresponsive NMIBC. Recorded live at Uromigos Live & Unplugged 2023 in Nashville, TN.
Episode 276: ESMO 2023 Highlights
Episode 275: Live meeting preview for #UromigosLive 2023 in Nashville
Brian and Tom discuss the benefits and risks of participating in the upcoming meeting . Uncertainty around it’s success are highlighted . Methods of attending remain opaque.
Episode 274: ESMO 2023 STEAP1/BiTE in CRPC shows promise
Episode 273: ESMO 2023 - Toripalimab and axitinib in clear cell RCC
Episode 272: ESMO 2023 - EV302 and CM901 in 1st line bladder cancer
Episode 271: ESMO 2023 - THOR: Erdafitinib in bladder cancer
Yohann Loriot described the 2 Thor randomised phase 3 studies